Cutaneous leishmaniasis. Cutaneous leishmaniasis
Conditions
Interventions
Intervention 1: Intervention group A: Patients were given drug via Intramuscular route injection meglumine antimoniate 15mg/kg if dose exceeds 10ml then it should be divided into two doses given on ea
Sponsors
CMH Quetta
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: All patients with biopsy proven leishmaniasis or has lesion(s) located in sites not compatible with local treatment for example lesions on or around eyes Disfiguring lesion on face that lead to scarring Lesions difficult to heal like on lower limbs Lesion more than 4cm in size with sporotichoid spread Multiple lesions
Exclusion criteria
Exclusion criteria: patients allergic to antimonials Pregnant and breast feeding patients Patients having mucosal, mucocutaneous or visceral leishmaniasis Patients with comorbids (diabetes, hypertension, chronic liver disease, chronic kidney disease) Immunosuppression patients Baseline ECG abnormalities/heart disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Healing of lesion in response to treatment. Timepoint: before intervention and 2, 4 , 6 and 8 weeks after intervention until complete healing occurs then patient called for followup after 4 weeks. Method of measurement: Clinical response. | — |
Countries
Pakistan
Contacts
Public ContactDr Zainab Kazam
CMH Quetta
Outcome results
None listed